Relypsa (NASDAQ: RLYP) will present results of sub-group analyses from the OPAL-HK study of Veltassa (patiromer) for oral suspension at the American Society of Nephrology's (ASN) Kidney Week 2015, taking place November 3 - 8 in San Diego, CA.
The event has been added to the Binary Event Calendar.
Veltassa was recently approved by the U.S. Food and Drug Administration (FDA) as the first new medicine for the treatment of hyperkalemia in more than 50 years.
Here's the release.
No comments:
Post a Comment